Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004713
Abstract: Background T-cell receptor-engineered T cells (TCR-Ts) have achieved encouraging success in anticancer clinical trials. The antigenic targets, however, were primarily focused on human leukocyte antigen (HLA) A*02:01 restricted epitopes from a few cancer/testis antigens (CTAs)…
read more here.
Keywords:
cell;
cancer;
high avidity;
common solid ... See more keywords